TheraVasc is developing a repurposed drug, TV1001, an oral formulation of sodium nitrite, to target patient populations with poor blood flow to the extremities, such as those with diabetic leg and foot problems or those with peripheral artery disease (PAD). While there is a large and growing number of patients suffering from such health problems, there is no effective treatment available. TV1001 has been shown to selectively promote the re-growth of blood vessels in ischemic tissues such as those affected in patients with diabetes or PAD.

Additional Investors:
GLIDE, JumpStart Ventures, Ohio TechAngels, Portal Capital, Physician Investment Group, The Biomedical Research Foundation